Family · Pharmaceutical analytical standards
Silodosin
A highly selective alpha-blocker for the alpha-1A receptors of the prostate, bladder and urethra, approved in Japan in 2006 and in the United States in 2008 for urinary symptoms of benign prostatic hyperplasia. This family brings together the active ingredient, metabolites, labelled standards, nitrosamines and other impurities.
Did you know?Its selectivity can be put in numbers: it binds alpha-1A receptors with an affinity more than 100 times higher than for other adrenergic receptors, and its glucuronide metabolite keeps about one eighth of that affinity.
No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.
